Joshua Ruch sold $6.1M of WGS
director at GeneDx Holdings Corp.. 38,000 shares at an average of $160.37, traded Nov 24, 2025, filed Nov 26, 2025.
Score components
- +15RoleDirector
- +25Trade size$6.1M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000943431-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: Kariba LLC | -201 | $158.40 | $32k | 14,644 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: Kariba LLC | -625 | $159.28 | $100k | 14,019 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: Kariba LLC | -889 | $160.45 | $143k | 13,130 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: Kariba LLC | -1,117 | $161.16 | $180k | 12,013 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: Kariba LLC | -72 | $162.04 | $12k | 11,941 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: Rugu2 LLC | -407 | $158.40 | $64k | 29,731 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: Rugu2 LLC | -1,268 | $159.28 | $202k | 28,463 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: Rugu2 LLC | -1,805 | $160.45 | $290k | 26,658 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: Rugu2 LLC | -2,268 | $161.16 | $366k | 24,390 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: Rugu2 LLC | -147 | $162.04 | $24k | 24,243 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: VAAL Investment Partners Q9 LP | -2,016 | $158.40 | $319k | 147,268 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: VAAL Investment Partners Q9 LP | -6,279 | $159.28 | $1.0M | 140,989 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: VAAL Investment Partners Q9 LP | -8,944 | $160.45 | $1.4M | 132,045 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: VAAL Investment Partners Q9 LP | -11,234 | $161.16 | $1.8M | 120,811 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: VAAL Investment Partners Q9 LP | -728 | $162.04 | $118k | 120,083 | Nov 26, 2025 |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 43Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.0M 10,501 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 39Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $557k 8,818 shares | -20% | |
| 53Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $3.0M 46,933 shares | -34% | |
| 37Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $438k 5,706 shares | -17% | |
| 48Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.3M 17,179 shares | -23% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $111k 1,280 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.